A Phase 2 interventional study of RO7568282 and Placebo in Parkinson's Disease, sponsored by Hoffmann-La Roche. Recruiting at 6 sites in 5 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 246 studies in Parkinson Disease with a site in United Kingdom — 55 open to participants now, 66 under way, 5 of them phase 3. Parkinson Disease · United Kingdom.
Among the 246 studies in Parkinson Disease with a site in United Kingdom, this one is the 17th largest by planned enrollment of the 183 interventional ones that give a count, is one of 11 that started in 2026, is one of 41 in phase 2, reaches primary completion later than 54 of the 65 other live ones, and was the 242nd registered.
4,580 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →55 of the 246 studies in Parkinson Disease with a site in United Kingdom are open now. Recruiting first, the newest first:
Northumbria University · Sites in United Kingdom
Ages 50+
Heriot-Watt University · Sites in United Kingdom
Ages 18+
Queen's University, Belfast · Sites in United Kingdom
Ages 18+
University Hospital Tuebingen · Sites in United Kingdom, France, Germany and 4 more countries
Ages 35–80
AbbVie · Sites in United Kingdom, United States, Canada and 6 more countries
Ages 18–69
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 750 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
246 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 48 · Phase 3 46 · Phase 4 6
First in 1999; this study’s year is marked. 11 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 474 is above the median of 40 across 3,358 interventional studies indexed under Parkinson Disease.
Median enrollment 80 across the 183 interventional studies, 100 across the 62 observational. Of the 152 that completed or were terminated, 45 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 246 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 5 studies filed under Parkinson Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Parkinson Disease with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05986643University of LeicesterBrain Training to Improve Balance in Parkinson's Disease | 2026-12 |
| NCT05635409Region SkaneA Trial to Determine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons to the Brains of Individuals With Parkinson's Disease | 2027-01 |
| NCT02760108University College, LondonParkinson's Families Project | 2027-01 |
| NCT07882108Cambridge University Hospitals NHS Foundation TrustGinger-PD: Ginger as a Modifier of Ghrelin Levels and Gut Function in Parkinson's Disease | 2027-03-01 |
| NCT07189468University Hospital, ToulouseAI-based Progression and Medication Response Prediction Study in Parkinson's Disease | 2027-04-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 246 studies in Parkinson Disease with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of RO7568282 compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other protocol-defined inclusion/exclusion criteria also apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RO7568282 will be administered as per the schedule specified in the protocol.
Drug: RO7568282
RO7568282 will be administered as per the schedule specified in the protocol.
Drug: RO7568282
Placebo will be administered as per the schedule specified in the protocol.
Drug: Placebo
RO7568282 will be administered as per the schedule specified in the protocol.
Placebo will be administered as per the schedule specified in the protocol.
Time to a Confirmed Motor Progression Event From the Randomization Date, as Measured by the MDS-UPDRS Part III Score
Time frame: Up to at least Week 104
Change in Motor Signs From Baseline at Week 104, as Measured by the MDS-UPDRS Part III Score
Time frame: Baseline and Week 104
Time to Worsening of Participants' Motor Function, as Reported by the Participant in the Presence of a Confirmed Motor Progression Event
Time frame: Up to at least Week 104
Incidence of Adverse Events (AEs)
Time frame: Up to at least Week 104
Change From Baseline in Columbia-suicide Severity Rating Scale (C-SSRS)
Time frame: Up to at least Week 104
Plasma Concentrations of RO7568282
Time frame: Up to at least Week 104
Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Started Nov 2026 (actual). Primary completion is estimated for Dec 2028, 25 months after the start.
Of 97 industry-sponsored phase 2 interventional studies under Parkinson Disease, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 33. This study's planned 25 months is above that.
Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.
Start moved twice since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, last on Nov 16, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.